inclusion criteria: * willing and able to provide written informed consent * in general good health as determined by the site clinician * negative sars-cov-2 test at screening * fully vaccinated for sars-cov-2 (does not include booster vaccination) * agree to abstain from any other investigational drug studies for the duration of the study * agree to abstain from nasally administered products, including over-the-counter products, for the duration of the study * report use of an effective method of contraception at enrollment and intending to continue use of an effective method for the duration of study participation. acceptable methods include: 1. males: male condoms, sterilization of participant or partner, partner use of hormonal contraception or intrauterine device, identifies as a man who has sex with men exclusively, and/or sexually abstinent for the past 60 days and agrees to remain abstinent for the study duration 2. females: hormonal methods at the time of enrollment, intrauterine device inserted prior to enrollment, sterilization of participant or partner, consistent condom use of male partner for at least 28 days (reports using condoms 10 times in the last 10 acts of intercourse), identifies as a woman who has sex with women exclusively, and/or sexually abstinent for the past 60 days and agrees to remain abstinent for the study duration. * agree to participate in all study-related assessments and procedures

inclusion criteria: * willing and able to provide written informed consent * in general good health as determined by the site clinician * negative sars-cov-2 test at screening * fully vaccinated for sars-cov-2 (does not include booster vaccination) * agree to abstain from any other investigational drug studies for the duration of the study * agree to abstain from nasally administered products, including over-the-counter products, for the duration of the study * report use of an effective method of contraception at enrollment and intending to continue use of an effective method for the duration of study participation. acceptable methods include: 1. males: male condoms, sterilization of participant or partner, partner use of hormonal contraception or intrauterine device, identifies as a man who has sex with men exclusively, and/or sexually abstinent for the past 60 days and agrees to remain abstinent for the study duration 2. females: hormonal methods at the time of enrollment, intrauterine device inserted prior to enrollment, sterilization of participant or partner, consistent condom use of male partner for at least 28 days (reports using condoms 10 times in the last 10 acts of intercourse), identifies as a woman who has sex with women exclusively, and/or sexually abstinent for the past 60 days and agrees to remain abstinent for the study duration. * agree to participate in all study-related assessments and procedures

inclusion criteria: willing and able to provide written informed consent in general good health as determined by the site clinician negative sars-cov-2 test at screening fully vaccinated for sars-cov-2 (does not include booster vaccination) agree to abstain from any other investigational drug studies for the duration of the study agree to abstain from nasally administered products, including over-the-counter products, for the duration of the study report use of an effective method of contraception at enrollment and intending to continue use of an effective method for the duration of study participation. acceptable methods include: males: male condoms, sterilization of participant or partner, partner use of hormonal contraception or intrauterine device, identifies as a man who has sex with men exclusively, and/or sexually abstinent for the past 60 days and agrees to remain abstinent for the study duration females: hormonal methods at the time of enrollment, intrauterine device inserted prior to enrollment, sterilization of participant or partner, consistent condom use of male partner for at least 28 days (reports using condoms 10 times in the last 10 acts of intercourse), identifies as a woman who has sex with women exclusively, and/or sexually abstinent for the past 60 days and agrees to remain abstinent for the study duration. agree to participate in all study-related assessments and procedures

inclusion criteria: willing and able to provide written informed consent in general good health as determined by the site clinician negative sars-cov-2 test at screening fully vaccinated for sars-cov-2 (does not include booster vaccination) agree to abstain from any other investigational drug studies for the duration of the study agree to abstain from nasally administered products, including over-the-counter products, for the duration of the study report use of an effective method of contraception at enrollment and intending to continue use of an effective method for the duration of study participation. acceptable methods include: males: male condoms, sterilization of participant or partner, partner use of hormonal contraception or intrauterine device, identifies as a man who has sex with men exclusively, and/or sexually abstinent for the past 60 days and agrees to remain abstinent for the study duration females: hormonal methods at the time of enrollment, intrauterine device inserted prior to enrollment, sterilization of participant or partner, consistent condom use of male partner for at least 28 days (reports using condoms 10 times in the last 10 acts of intercourse), identifies as a woman who has sex with women exclusively, and/or sexually abstinent for the past 60 days and agrees to remain abstinent for the study duration. agree to participate in all study-related assessments and procedures